Orgenesis Inc. Interest Expense (Operating)

Interest Expense (Operating) of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Interest Expense (Operating) growth rates and interactive chart.


Highlights and Quick Summary

  • Interest Expense (Operating) for the quarter ending September 29, 2021 was $2.12 Million (a 690.67% increase compared to previous quarter)
  • Year-over-year quarterly Interest Expense (Operating) increased by 858.82%
  • Annual Interest Expense (Operating) for 2020 was $1.09 Million (a 962.14% increase from previous year)
  • Annual Interest Expense (Operating) for 2019 was $103 Thousand (a -96.26% decrease from previous year)
  • Annual Interest Expense (Operating) for 2018 was $2.75 Million (a 123.28% increase from previous year)
  • Twelve month Interest Expense (Operating) ending September 29, 2021 was $2.79 Million (a 229.59% increase compared to previous quarter)
  • Twelve month trailing Interest Expense (Operating) increased by 209.1% year-over-year
Trailing Interest Expense (Operating) for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$2.79 Million $845 Thousand $806 Thousand $901 Thousand
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Interest Expense (Operating) of Orgenesis Inc.

Most recent Interest Expense (Operating)of ORGS including historical data for past 10 years.

Interactive Chart of Interest Expense (Operating) of Orgenesis Inc.

Orgenesis Inc. Interest Expense (Operating) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $2.12 $0.27 $0.18
2020 $0.22 $0.18 $0.23 $0.27 $1.09
2019 $0.29 $0.1
2018 $2.75
2017 $1.23
2016 $0.69

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.